GSK Investigational Site

Bengbu 233000

0 studies enrolling now · 2 studies all time

What they study most

Neoplasms, Head and Neck, Pulmonary Disease, Chronic Obstructive

Studies at this site

• Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Stopped early
• Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease — Completed